Last reviewed · How we verify
Servent Diskus
Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow.
Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow. Used for Maintenance treatment of asthma, Maintenance treatment of chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Servent Diskus |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Salmeterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. The Diskus is a dry powder inhaler formulation that delivers salmeterol directly to the lungs for local action. It is used as a maintenance therapy for chronic airway obstruction, typically in combination with inhaled corticosteroids.
Approved indications
- Maintenance treatment of asthma
- Maintenance treatment of chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Muscle cramps
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |